Trevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics to Participate in Upcoming Conferences
NEW HAVEN, Conn., May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor, business development and medical conferences in May and June.
康涅狄格州紐黑文,2024 年 5 月 9 日/PRNewswire/-- Trevi Therapeutics, In 納斯達克股票代碼:TRVI)是一家處於臨床階段的生物製藥公司,該公司正在開發用於治療特發性肺纖維化(IPF)和難治性慢性咳嗽(RCC)的研究性療法Haduvio(口服納布啡ER),今天宣佈,高級管理層將在5月和6月參加投資者、業務發展和醫學會議。
The Citizens JMP Life Sciences Conference
May 13-14, 2024, New York, NY
Corporate Presentation: May 14 at 12:00 p.m. ET
Trevi Presenter: Jennifer Good, President and CEO
Citizens JMP 生命科學會議
2024 年 5 月 13-14 日,紐約州紐約
企業演示: 美國東部時間 5 月 14 日中午 12:00
特雷維主持人: 總裁兼首席執行官詹妮弗·古德
ATS 2024 International Conference
May 17-22, 2024, San Diego, CA
Session: A104: Advances in the Diagnosis and Treatment of ILD
Abstract: Nalbuphine Extended-release Reduces Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis
Presentation: May 19, 3:00 p.m. - 4:15 p.m. PT
Location: San Diego Convention Center, Room 33A-C (Upper Level)
Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust. Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.
ATS 2024 國際會議
2024 年 5 月 17 日至 22 日,加利福尼亞州聖地亞哥
會話: A104:ILD 診斷和治療的進展
摘要: 納布啡緩釋可減少特發性肺纖維化患者的咳嗽發作
演示: 太平洋時間 5 月 19 日下午 3:00-下午 4:15
地點: 聖地亞哥會議中心,33A-C 室(上層)
演示者: 傑基·史密斯,MB、ChB、FRCP、博士,曼徹斯特大學呼吸醫學教授,曼徹斯特大學NHS基金會信託基金榮譽顧問。美國國立衛生研究院曼徹斯特臨床研究機構主任、美國國立衛生研究院曼徹斯特生物醫學研究中心呼吸學主題負責人和美國國立衛生研究院高級研究員。
Registration details: https://conference.thoracic.org/
Life Science Education Series: Chronic Cough – KOL Panel Discussion
Discussion: May 20, 12:30 p.m. - 2:30 p.m. PT
Location: San Diego, CA
Panel Members: Experts in the field of chronic cough include Professor Peter Dicpinigaitis, Professor Jacky Smith, and Professor Alyn Morice. Moderated by Oppenheimer's Senior Biotechnology Analyst Dr. Leland Gershell.
生命科學教育系列:慢性咳嗽 — KOL 小組討論
討論: 太平洋時間 5 月 20 日下午 12:30-下午 2:30
地點: 加利福尼亞州聖地亞哥
小組成員: 慢性咳嗽領域的專家包括彼得·迪皮尼蓋蒂斯教授、傑基·史密斯教授和艾琳·莫里斯教授。由奧本海默的高級生物技術分析師利蘭·格謝爾博士主持。
To register, email: k.mcmanus@trevitherapeutics.com
要註冊,請發送電子郵件至: k.mcmanus@trevitherapeutics.com
2024 BIO International Convention
June 3-6, 2024, San Diego, CA
2024 BIO 國際大會
2024 年 6 月 3 日至 6 日,加利福尼亞州聖地亞哥
Oppenheimer's 2024 Montauk Life Sciences Summit
June 26-28, 2024, Montauk, NY
奧本海默的 2024 年蒙托克生命科學峯會
2024 年 6 月 26 日至 28 日,紐約州蒙托克
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi is also developing Haduvio for prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and μ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough.
關於 Trevi Therapeutics, Inc
Trevi Therapeutics, Inc. 是一家處於臨床階段的生物製藥公司,正在開發研究性療法Haduvio(口服納布啡ER),用於治療特發性肺纖維化(IPF)和難治性慢性咳嗽(RCC)中的慢性咳嗽。特雷維還在爲結節性瘙癢症開發Haduvio。Haduvio 是一種雙重阿片類藥物受體激動劑和 μ-阿片受體拮抗劑,可在大腦中樞和肺部外周起作用,有可能產生協同鎮咳作用,治療慢性咳嗽。
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US.
慢性咳嗽的影響是巨大的,通常會導致患者的社交、身體和心理生活質量下降。在IPF中,慢性咳嗽可能導致疾病惡化,並可能增加進展、死亡或需要進行肺移植的風險。IPF中沒有經批准的治療慢性咳嗽的療法,目前的治療方案對患者的緩解作用微乎其微。RCC影響多達10%的成年人群,而Haduvio向RCC的擴展有可能惠及患有中度至重度慢性咳嗽的患者。美國也沒有批准的RCC療法。
Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
美國緝毒局沒有計劃注射腸外納布啡。特雷維打算提議將Haduvio作爲口服納布啡ER的商品名。其安全性和有效性尚未經過任何監管機構的評估。
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
欲了解更多信息,請訪問 www.treviTherapeutic 然後關注 Trevi X (以前是 Twitter)和 領英。
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
投資者聯繫人
凱蒂·麥克馬納斯
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
媒體聯繫人
羅莎莉亞·斯坎波利
914-815-1465
rscampoli@marketcompr.com
SOURCE Trevi Therapeutics, Inc.
來源 Trevi Therapeutics, Inc